成熟至关重要：成熟对树突状细胞疫苗抗肿瘤免疫的重要性 - Suppr

Suppr

超能文献

Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines.

作者信息

Adams Sylvia, O'Neill David, Bhardwaj Nina

出版信息

J Clin Oncol. 2004 Sep 15;22(18):3834-5; author reply 3835. doi: 10.1200/JCO.2004.99.019.

DOI:10.1200/JCO.2004.99.019

PMID:15365084

Abstract

摘要

相似文献

Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines.

J Clin Oncol. 2004 Sep 15;22(18):3834-5; author reply 3835. doi: 10.1200/JCO.2004.99.019.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

J Immunother. 2006 Sep-Oct;29(5):545-57. doi: 10.1097/01.cji.0000211309.90621.8b.

Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.

Melanoma Res. 2008 Apr;18(2):104-11. doi: 10.1097/CMR.0b013e3282f702cf.

[Vaccination therapy of melanoma].

J Dtsch Dermatol Ges. 2005 Aug;3(8):630-45. doi: 10.1111/j.1610-0387.2005.05528.x.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Gene Ther. 2006 Jul;13(13):1010-20. doi: 10.1038/sj.gt.3302759. Epub 2006 Mar 9.

Melanoma vaccines.

Dermatol Online J. 2000 Sep;6(1):5.

Dendritic cell therapy for skin cancer.

Vox Sang. 2004 Jul;87 Suppl 2:112-4. doi: 10.1111/j.1741-6892.2004.00465.x.

Getting melanoma cells to stimulate with frequency.

J Clin Oncol. 2005 Dec 10;23(35):8929-31. doi: 10.1200/JCO.2005.03.8307. Epub 2005 Oct 31.

Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.

Clin Cancer Res. 2006 Dec 15;12(24):7380-8. doi: 10.1158/1078-0432.CCR-06-1879.

Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.

Cancer. 2007 Jul 1;110(1):203-14. doi: 10.1002/cncr.22744.

引用本文的文献

Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Exp Mol Med. 2013 Feb 8;45(2):e8. doi: 10.1038/emm.2013.14.

Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

Cancer Res. 2008 Nov 15;68(22):9441-50. doi: 10.1158/0008-5472.CAN-08-0900.

A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.

J Transl Med. 2008 Jan 25;6:6. doi: 10.1186/1479-5876-6-6.

Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1.

J Leukoc Biol. 2007 Jul;82(1):44-56. doi: 10.1189/jlb.1006641. Epub 2007 Apr 18.

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients.

J Transl Med. 2006 Aug 16;4:36. doi: 10.1186/1479-5876-4-36.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验